Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.50 |
| ▸ | FLT3 | P36888 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24574168 | 0.90 | USP30 (0.44) | IRAK4FLT3USP30 | |
| SCHEMBL24231556 | 0.89 | FLT3 (0.43) | IRAK4FLT3USP30IGF1R | |
| SCHEMBL26359559 | 0.89 | FLT3 (0.54) | IRAK4FLT3USP30 | |
| SCHEMBL24231551 | 0.88 | FLT3 (0.53) | IRAK4FLT3USP30IGF1R | |
| SCHEMBL26358853 | 0.88 | FLT3 (0.49) | IRAK4FLT3USP30 | |
| SCHEMBL26358740 | 0.88 | FLT3 (0.49) | IRAK4FLT3USP30 | |
| SCHEMBL24231685 | 0.88 | FLT3 (0.42) | IRAK4FLT3USP30 | |
| SCHEMBL24231627 | 0.88 | FLT3 (0.56) | IRAK4FLT3USP30IGF1R | |
| SCHEMBL29372530 | 0.88 | USP30 (0.48) | IRAK4FLT3USP30 | |
| SCHEMBL24231566 | 0.88 | USP30 (0.48) | IRAK4FLT3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| WO-2022026935-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026935-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | IRAK4 5/4885FLT3 1/4885USP30 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.